Median PFS in the pembrolizumab–chemotherapy group was 6.3 months (95% CI 6.0–8.2) versus 6.0 months (4.2–6.2) in the placebo–chemotherapy group in all randomly assigned patients (HR, 0.57; 95% CI 0.39–0.83) (Fig. 2a), 6.4 months (6.0–8.4) versus 6.1 months (4.2–6.3) in patients with ESCC (0.56; 0.37–0.83) (Fig. 2b), and 8.2 months (6.0–10.4) versus 4.3 months (3.9–6.0) in patients with PD-L1 CPS ≥ 10 (0.36; 0.21–0.61) (Fig. 2c). Here, CD274 is linked to esophageal squamous cell carcinoma.